Here are the DEF 14A proxy statements from AnaptysBio, Inc. (ANAB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ANAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANAB filings page.
AnaptysBio, Inc. is asking stockholders to vote at the August 11, 2026 annual meeting on four key items. Stockholders will elect two Class III directors to three-year terms, ratify KPMG LLP as auditor for the fiscal year ending June 30, 2027, and cast an advisory Say‑on‑Pay vote on executive compensation.
The company also seeks approval of an amendment to its 2017 Equity Incentive Plan that extends the plan’s term by 10 years, to June 20, 2036, and adds annual compensation caps for non‑employee directors of $1,000,000 in their first fiscal year of service and $750,000 in later years, starting with fiscal years beginning July 1, 2026. The amendment does not increase the plan’s existing share reserve. As of June 22, 2026, 29,608,481 common shares were outstanding and entitled to vote.